ImmuPharma plc (LON:IMM – Get Free Report) shares rose 8.6% during trading on Friday. The stock traded as high as GBX 3.61 and last traded at GBX 3.26. Approximately 8,074,562 shares changed hands during mid-day trading, an increase of 224% from the average daily volume of 2,488,500 shares. The stock had previously closed at GBX 3.
ImmuPharma Stock Performance
The firm has a market capitalization of £20.63 million, a P/E ratio of -3.98 and a beta of 3.02. The stock has a fifty day moving average price of GBX 3.61 and a two-hundred day moving average price of GBX 4.67.
ImmuPharma (LON:IMM – Get Free Report) last released its quarterly earnings data on Tuesday, September 15th. The company reported GBX (0.84) EPS for the quarter. ImmuPharma had a negative return on equity of 559.87% and a net margin of 3,519.56%. As a group, research analysts anticipate that ImmuPharma plc will post -339.00 earnings per share for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
- Block by Block: Cash App Builds a Stronger Foundation
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
